Ianalumab,iscalimab
Novartis
['ianalumab']
#eular2023 #pos0120 from sjogren to sle. interim analysis of phase 2 rct showed primary endpoint, sri-4 + ability to sustain pred dose to 5 mg/d or bl from wk16 to 28 was achieved more in ianalumab (bcell depletion &amp; baff-r-i) vs pbo (44% vs 9%). advance to phase 3 
Rheumatologist. Interested in B-cells, Lupus, Sjogren, Pre-Connective Tissue Disease, Tennis, Running & Travelling 🌏